氯氮平与GABAB受体结合:临床与结构见解
氯氮平是难治性精神分裂症的金标准药物,但作用机制尚不明确。该文通过GABAB受体X射线晶体结构分析与分子对接计算,提示氯氮平可能像巴氯芬一样直接结合GABAB受体,这一发现有助于理解氯氮平的药理学独特性及开发难治性精神分裂症生物标志物和更靶向的治疗。
要点
- 氯氮平可能直接结合GABAB受体,类似巴氯芬。
- GABAB受体可能参与精神分裂症发病机制。
- 该发现或推动难治性精神分裂症生物标志物与个体化治疗。
核心结论
- 氯氮平可能通过直接结合GABAB受体介导其作用,类似巴氯芬。
研究设计与样本
- 基于GABAB受体X射线晶体结构分析与分子对接计算的结构研究。
主要发现
- 分子对接计算提示氯氮平可与GABAB受体直接结合,结合方式与巴氯芬相似。
临床怎么用
- 该机制假说或有助于理解氯氮平的药理学独特性并推动难治性精神分裂症生物标志物开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clozapine is the gold-standard agent for treatment resistant schizophrenia but its mechanism of action remains unclear. There is emerging evidence of the potential role of the GABAB receptor in the pathogenesis of schizophrenia. It has been hypothesised that clozapine can mediate its actions via the GABAB receptor. Baclofen is currently recognised as the prototype GABAB receptor agonist. There are some potential clinical similarities between clozapine and baclofen. Indeed, baclofen has been previously proposed for use as an antipsychotic agent. Our analysis of the X-ray crystal structure of GABAB receptor along with molecular docking calculations, suggests that clozapine could directly bind to the GABAB receptor similar to that of baclofen. This finding could lead to a better understanding of the pharmacological uniqueness of clozapine, potential development of a biomarker for treatment resistant schizophrenia and the development of more targeted treatments leading to personalisation of treatment.
引用
- Nair PC, McKinnon RA, Miners JO, et al. Binding of clozapine to the GABAB receptor: clinical and structural insights. Mol Psychiatry. 2020. PMID: 32203158. doi:10.1038/s41380-020-0709-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。